Heparin as adjunctive therapy to coronary thrombolysis in acute myocardial infarction.
For many years anticoagulation has played a role in the prevention and management of thromboembolic complications associated with acute myocardial infarction. However, the role of heparin therapy after pharmacologic thrombolysis in myocardial infarction remains controversial. Debate continues regarding the necessity of heparin treatment after thrombolytic therapy as well as the mode by which it is administered. The purpose of this review is to summarize the findings of clinical trials designed to evaluate the effectiveness and safety of heparin as an adjuvant agent to thrombolytic therapy in acute myocardial infarction. Data regarding the clinical effectiveness of heparin are presented. Information and recommendations regarding the optimal dose, route of administration, timing of initiation, and duration of heparin treatment are provided.
Bowlby
H
H
University of Illinois College of Pharmacy, Chicago, USA.
Hisle
K
K
Clifton
G D
GD
D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006493:Heparin / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000451:nursing; D016032:Randomized Controlled Trials as Topic; D015912:Thrombolytic Therapy / Q000451:nursing*; D016896:Treatment Outcome
D006493:Heparin